Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy

Shuyang Sun,1,2 Ziqiang Ding,1 Xiaomei Yang,1,3 Xinyue Zhao,1,3 Minlong Zhao,1,2 Li Gao,1,3 Qu Chen,1,2 Shenxia Xie,1,4 Aiqun Liu,1 Shihua Yin,1 Zhiping Xu,5 Xiaoling Lu1,2 1International Nanobody Research Center, Guangxi Medical University, Nanning, Guangxi, 530021, People’s Republic of C...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sun S, Ding Z, Yang X, Zhao X, Zhao M, Gao L, Chen Q, Xie S, Liu A, Yin S, Xu Z, Lu X
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2021
Materias:
Acceso en línea:https://doaj.org/article/11bc00393d174e669556d9276f8def05
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:11bc00393d174e669556d9276f8def05
record_format dspace
spelling oai:doaj.org-article:11bc00393d174e669556d9276f8def052021-12-02T14:39:49ZNanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy1178-2013https://doaj.org/article/11bc00393d174e669556d9276f8def052021-03-01T00:00:00Zhttps://www.dovepress.com/nanobody-a-small-antibody-with-big-implications-for-tumor-therapeutic--peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Shuyang Sun,1,2 Ziqiang Ding,1 Xiaomei Yang,1,3 Xinyue Zhao,1,3 Minlong Zhao,1,2 Li Gao,1,3 Qu Chen,1,2 Shenxia Xie,1,4 Aiqun Liu,1 Shihua Yin,1 Zhiping Xu,5 Xiaoling Lu1,2 1International Nanobody Research Center, Guangxi Medical University, Nanning, Guangxi, 530021, People’s Republic of China; 2School of Stomatology, Guangxi Medical University, Nanning, Guangxi, 530021, People’s Republic of China; 3School of Preclinical Medicine, Guangxi Medical University, Nanning, Guangxi, 530021, People’s Republic of China; 4Department of Pharmacology, Guangxi Medical University, Nanning, Guangxi, 530021, People’s Republic of China; 5Australian Institute for Bioengineering and Nanotechnology, University of Queensland, St Lucia, QLD, 4072, AustraliaCorrespondence: Xiaoling LuNanobody Research Center, Guangxi Medical University, Nanning, Guangxi, 530021, People’s Republic of ChinaTel/Fax +86 771-2387 518Email luxiaoling@gxmu.edu.cnZhiping XuAustralian Institute for Bioengineering and Nanotechnology, University of Queensland, St Lucia, QLD, 4072, AustraliaEmail gordonxu@uq.edu.auAbstract: The development of monoclonal antibody treatments for successful tumor-targeted therapies took several decades. However, the efficacy of antibody-based therapy is still confined and desperately needs further improvement. Nanobodies are the recombinant variable domains of heavy-chain-only antibodies, with many unique properties such as small size (∼ 15kDa), excellent solubility, superior stability, ease of manufacture, quick clearance from blood, and deep tissue penetration, which gain increasing acceptance as therapeutical tools and are considered also as building blocks for chimeric antigen receptors as well as for targeted drug delivery. Thus, one of the promising novel developments that may address the deficiency of monoclonal antibody-based therapies is the utilization of nanobodies. This article provides readers the significant factors that the structural and biochemical properties of nanobodies and the research progress on nanobodies in the fields of tumor treatment, as well as their application prospect.Keywords: nanobody, drug delivery, immunotherapy, CAR-T, tumor treatmentSun SDing ZYang XZhao XZhao MGao LChen QXie SLiu AYin SXu ZLu XDove Medical Pressarticlenanobodydrug deliveryimmunotherapycar-ttumor treatmentMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 16, Pp 2337-2356 (2021)
institution DOAJ
collection DOAJ
language EN
topic nanobody
drug delivery
immunotherapy
car-t
tumor treatment
Medicine (General)
R5-920
spellingShingle nanobody
drug delivery
immunotherapy
car-t
tumor treatment
Medicine (General)
R5-920
Sun S
Ding Z
Yang X
Zhao X
Zhao M
Gao L
Chen Q
Xie S
Liu A
Yin S
Xu Z
Lu X
Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy
description Shuyang Sun,1,2 Ziqiang Ding,1 Xiaomei Yang,1,3 Xinyue Zhao,1,3 Minlong Zhao,1,2 Li Gao,1,3 Qu Chen,1,2 Shenxia Xie,1,4 Aiqun Liu,1 Shihua Yin,1 Zhiping Xu,5 Xiaoling Lu1,2 1International Nanobody Research Center, Guangxi Medical University, Nanning, Guangxi, 530021, People’s Republic of China; 2School of Stomatology, Guangxi Medical University, Nanning, Guangxi, 530021, People’s Republic of China; 3School of Preclinical Medicine, Guangxi Medical University, Nanning, Guangxi, 530021, People’s Republic of China; 4Department of Pharmacology, Guangxi Medical University, Nanning, Guangxi, 530021, People’s Republic of China; 5Australian Institute for Bioengineering and Nanotechnology, University of Queensland, St Lucia, QLD, 4072, AustraliaCorrespondence: Xiaoling LuNanobody Research Center, Guangxi Medical University, Nanning, Guangxi, 530021, People’s Republic of ChinaTel/Fax +86 771-2387 518Email luxiaoling@gxmu.edu.cnZhiping XuAustralian Institute for Bioengineering and Nanotechnology, University of Queensland, St Lucia, QLD, 4072, AustraliaEmail gordonxu@uq.edu.auAbstract: The development of monoclonal antibody treatments for successful tumor-targeted therapies took several decades. However, the efficacy of antibody-based therapy is still confined and desperately needs further improvement. Nanobodies are the recombinant variable domains of heavy-chain-only antibodies, with many unique properties such as small size (∼ 15kDa), excellent solubility, superior stability, ease of manufacture, quick clearance from blood, and deep tissue penetration, which gain increasing acceptance as therapeutical tools and are considered also as building blocks for chimeric antigen receptors as well as for targeted drug delivery. Thus, one of the promising novel developments that may address the deficiency of monoclonal antibody-based therapies is the utilization of nanobodies. This article provides readers the significant factors that the structural and biochemical properties of nanobodies and the research progress on nanobodies in the fields of tumor treatment, as well as their application prospect.Keywords: nanobody, drug delivery, immunotherapy, CAR-T, tumor treatment
format article
author Sun S
Ding Z
Yang X
Zhao X
Zhao M
Gao L
Chen Q
Xie S
Liu A
Yin S
Xu Z
Lu X
author_facet Sun S
Ding Z
Yang X
Zhao X
Zhao M
Gao L
Chen Q
Xie S
Liu A
Yin S
Xu Z
Lu X
author_sort Sun S
title Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy
title_short Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy
title_full Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy
title_fullStr Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy
title_full_unstemmed Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy
title_sort nanobody: a small antibody with big implications for tumor therapeutic strategy
publisher Dove Medical Press
publishDate 2021
url https://doaj.org/article/11bc00393d174e669556d9276f8def05
work_keys_str_mv AT suns nanobodyasmallantibodywithbigimplicationsfortumortherapeuticstrategy
AT dingz nanobodyasmallantibodywithbigimplicationsfortumortherapeuticstrategy
AT yangx nanobodyasmallantibodywithbigimplicationsfortumortherapeuticstrategy
AT zhaox nanobodyasmallantibodywithbigimplicationsfortumortherapeuticstrategy
AT zhaom nanobodyasmallantibodywithbigimplicationsfortumortherapeuticstrategy
AT gaol nanobodyasmallantibodywithbigimplicationsfortumortherapeuticstrategy
AT chenq nanobodyasmallantibodywithbigimplicationsfortumortherapeuticstrategy
AT xies nanobodyasmallantibodywithbigimplicationsfortumortherapeuticstrategy
AT liua nanobodyasmallantibodywithbigimplicationsfortumortherapeuticstrategy
AT yins nanobodyasmallantibodywithbigimplicationsfortumortherapeuticstrategy
AT xuz nanobodyasmallantibodywithbigimplicationsfortumortherapeuticstrategy
AT lux nanobodyasmallantibodywithbigimplicationsfortumortherapeuticstrategy
_version_ 1718390459388133376